Advertisement
Heart, Lung and Circulation

Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges

  • Author Footnotes
    1 MBBS student.
    Fiona Thoi
    Footnotes
    1 MBBS student.
    Affiliations
    School of Medicine, University of Adelaide, Adelaide, SA, Australia
    Search for articles by this author
  • Daniel J. Scherer
    Affiliations
    Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA, Australia

    Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
    Search for articles by this author
  • David M. Kaye
    Affiliations
    Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, SA, Australia

    Department of Clinical Research, The Baker Heart and Diabetes Institute; Department of Cardiology, The Alfred Hospital; Department of Medicine, Monash University, Melbourne, Vic, Australia
    Search for articles by this author
  • Prashanthan Sanders
    Affiliations
    School of Medicine, University of Adelaide, Adelaide, SA, Australia

    Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA, Australia

    Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia

    Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, SA, Australia
    Search for articles by this author
  • Michael B. Stokes
    Correspondence
    Corresponding author at: Department of Cardiology, Royal Adelaide Hospital, Port Road, Adelaide, SA, Australia, 5000
    Affiliations
    School of Medicine, University of Adelaide, Adelaide, SA, Australia

    Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA, Australia

    Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia

    Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, SA, Australia
    Search for articles by this author
  • Author Footnotes
    1 MBBS student.
Published:February 10, 2022DOI:https://doi.org/10.1016/j.hlc.2021.12.015
      The growth in methamphetamine usage worldwide continues to present increasing societal and health care challenges. With the escalation of its usage in a variety of social demographics, the entity of methamphetamine-associated cardiomyopathy (MA-CMP) has emerged. This entity is increasingly responsible for an important proportion of heart failure burden in both admissions to hospital and in those individuals requiring chronic heart failure care. MA-CMP poses some unique challenges including its recognition, particularly in younger patients presenting with new-onset heart failure, its severity at presentation and complications as well as management options. The challenging nature of methamphetamine addiction and the necessity to achieve abstinence is a fundamental aspect of management of this condition. As methamphetamine use continues at high levels in Australia, the burden of MA-CMP will inevitably increase and, therefore, all clinicians responsible for heart failure management require an awareness of this disease entity and the specific clinical challenges of its care.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • AIHW
        Alcohol, tobacco & other drugs in Australia, Meth/amphetamine and other stimulants - Australian Institute of Health and Welfare.
        2020
        • Whetton S.
        • Shanahan M.
        • Cartwright K.
        • Duraisingam V.
        • Ferrante A.
        • Gray D.
        • et al.
        The Social Costs of Methamphetamine in Australia 2013/14 Perth.
        Curtin University, Western Australia2016
      1. Health. Patterns of use and harms associated with specific populations of methamphetamine users in Australia - exploratory research 2008. https://www1.health.gov.au/internet/publications/publishing.nsf/Content/phd-npi-methamphetamine-. [accessed 15.9.20].

        • Westmore T.V.V.J.
        • Thomson N.
        • Griffiths P.
        • Ryan J.
        Impacts of methamphetamine in Victoria: a community assessment.
        Penington Institute Report, 2014
        • Parish T.
        ‘Ice Epidemic?’ How increased purity of crystal meth explains Victoria’s rising methamphetamine related harms Melbourne VIC.
        Burnet Institute, 2014
        • Degenhardt L.
        • Roxburgh A.
        • Black E.
        • Bruno R.
        • Campbell G.
        • Kinner S.
        • et al.
        The epidemiology of methamphetamine use and harm in Australia.
        Drug Alcohol Rev. 2008; 27: 243-252
        • Nishimura M.
        • Ma J.
        • Fox S.
        • Toomu A.
        • Mojaver S.
        • Juang D.K.
        • et al.
        Characteristics and outcomes of methamphetamine abuse among veterans with heart failure.
        Am J Cardiol. 2019; 124: 907-911
        • Thomas I.C.
        • Nishimura M.
        • Ma J.
        • Dickson S.D.
        • Alshawabkeh L.
        • Adler E.
        • et al.
        Clinical ß.
        J Card Fail. 2020; 26: 202-209
        • Kevil C.G.
        • Goeders N.E.
        • Woolard M.D.
        • Bhuiyan M.S.
        • Dominic P.
        • Kolluru G.K.
        • et al.
        Methamphetamine use and cardiovascular disease.
        Arterioscler Thromb Vasc Biol. 2019; 39: 1739-1746
        • Zhao S.X.
        • Kwong C.
        • Swaminathan A.
        • Gohil A.
        • Crawford M.H.
        Clinical characteristics and outcome of methamphetamine-associated pulmonary arterial hypertension and dilated cardiomyopathy.
        JACC Heart Fail. 2018; 6: 209-218
        • Goodwin J.S.
        • Larson G.A.
        • Swant J.
        • Sen N.
        • Javitch J.A.
        • Zahniser N.R.
        • et al.
        Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo.
        J Biol Chem. 2009; 284: 2978-2989
        • Reese E.A.
        • Bunzow J.R.
        • Arttamangkul S.
        • Sonders M.S.
        • Grandy D.K.
        Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.
        J Pharmacol Exp Ther. 2007; 321: 178-186
        • U'Prichard D.C.
        • Greenberg D.A.
        • Snyder S.H.
        Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.
        Mol Pharmacol. 1977; 13: 454-473
        • Nguyen E.C.
        • McCracken K.A.
        • Liu Y.
        • Pouw B.
        • Matsumoto R.R.
        Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies.
        Neuropharmacology. 2005; 49: 638-645
        • Reddy P.K.V.
        • Ng T.M.H.
        • Oh E.E.
        • Moady G.
        • Elkayam U.
        Clinical characteristics and management of methamphetamine-associated cardiomyopathy: state-of-the-art review.
        J Am Heart Assoc. 2020; 9e016704
        • Giv M.J.
        Exposure to amphetamines leads to development of amphetamine type stimulants associated cardiomyopathy (ATSAC).
        Cardiovasc Toxicol. 2017; 17: 13-24
        • Lord K.C.
        • Shenouda S.K.
        • McIlwain E.
        • Charalampidis D.
        • Lucchesi P.A.
        • Varner K.J.
        Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction.
        Cardiovasc Res. 2010; 87: 111-118
        • Karch S.B.
        The unique histology of methamphetamine cardiomyopathy: a case report.
        Forensic Sci Int. 2011; 212: e1-e4
        • Schürer S.
        • Klingel K.
        • Sandri M.
        • Majunke N.
        • Besler C.
        • Kandolf R.
        • et al.
        Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy.
        JACC Heart Fail. 2017; 5: 435-445
        • He S.-Y.
        • Matoba R.
        • Fujitani N.
        • Sodesaki K.-i.
        • Onishi S.
        Cardiac muscle lesions associated with chronic administration of methamphetamine in rats.
        Am J Forensic Med Pathol. 1996; 17: 155-162
        • Chen J.P.
        Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm.
        J Invasive Cardiol. 2007; 19: E89-E92
        • Ito H.
        • Yeo K.K.
        • Wijetunga M.
        • Seto T.B.
        • Tay K.
        • Schatz I.J.
        A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse.
        Clin Cardiol. 2009; 32: E18-E22
        • Akhgari M.
        • Mobaraki H.
        • Etemadi-Aleagha A.
        Histopathological study of cardiac lesions in methamphetamine poisoning-related deaths.
        Daru. 2017; 25: 5
        • Rorabaugh B.R.
        • Seeley S.L.
        • Stoops T.S.
        • D'Souza M.S.
        Repeated exposure to methamphetamine induces sex-dependent hypersensitivity to ischemic injury in the adult rat heart.
        PloS One. 2017; 12: e0179129-e
        • Chavva H.
        • Brazeau D.A.
        • Denvir J.
        • Primerano D.A.
        • Fan J.
        • Seeley S.L.
        • et al.
        Methamphetamine-induced changes in myocardial gene transcription are sex-dependent.
        BMC Genomics. 2021; 22: 259
        • Matoba R.
        [Cardiac lesions in methamphetamine abusers].
        Nihon Hoigaku Zasshi. 2001; 55: 321-330
        • Abdullah C.S.
        • Aishwarya R.
        • Alam S.
        • Morshed M.
        • Remex N.S.
        • Nitu S.
        • et al.
        Methamphetamine induces cardiomyopathy by Sigmar1 inhibition-dependent impairment of mitochondrial dynamics and function.
        Commun Biol. 2020; 3: 682
      2. National wastewater drug monitoring program: report 7, April 2019. 2019
        • Richards J.R.
        • Harms B.N.
        • Kelly A.
        • Turnipseed S.D.
        Methamphetamine use and heart failure: Prevalence, risk factors and predictors.
        Am J Emerg Med. 2018; 36: 1423-1428
        • Yeo K.K.
        • Wijetunga M.
        • Ito H.
        • Efird J.T.
        • Tay K.
        • Seto T.B.
        • et al.
        The association of methamphetamine use and cardiomyopathy in young patients.
        Am J Med. 2007; 120: 165-171
        • Wang T.K.M.
        • Kueh S.A.
        • Sutton T.
        • Gabriel R.
        • Lund M.
        • Looi J.L.
        Poor outcomes in methamphetamine-associated cardiomyopathy-a growing health issue in New Zealand.
        N Z Med J. 2019; 132: 55-66
      3. Qutrio Baloch Z, Hussain M, Agha Abbas S, Perez JL, Ayyaz M. Methamphetamine-induced cardiomyopathy (MACM) in a middle-aged man; a case report. Emerg (Tehran). 62018. p. e9.

        • Albertson T.E.
        • Derlet R.W.
        • Van Hoozen B.E.
        Methamphetamine and the expanding complications of amphetamines.
        West J Med. 1999; 170: 214
        • Darke S.
        • Degenhardt L.
        • Mattick R.
        Mortality amongst illicit drug users: epidemiology, causes and intervention.
        Cambridge University Press, 2006
        • Haufroid V.
        • Hantson P.
        CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
        Clin Toxicol (Phila). 2015; 53: 501-510
        • Sutter M.E.
        • Gaedigk A.
        • Albertson T.E.
        • Southard J.
        • Owen K.P.
        • Mills L.D.
        • et al.
        Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.
        Clin Toxicol (Phila). 2013; 51: 540-544
        • Bhuiyan M.S.
        • Tagashira H.
        • Fukunaga K.
        Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure.
        J Pharmacol Sci. 2013; 121: 177-184
        • Bhuiyan M.S.
        • Tagashira H.
        • Shioda N.
        • Fukunaga K.
        Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions.
        Expert Opin Ther Targets. 2010; 14: 1009-1022
        • Abdullah C.S.
        • Alam S.
        • Aishwarya R.
        • Miriyala S.
        • Panchatcharam M.
        • Bhuiyan M.A.N.
        • et al.
        Cardiac dysfunction in the sigma 1 receptor knockout mouse associated with impaired mitochondrial dynamics and bioenergetics.
        J Am Heart Assoc. 2018; 7e009775
        • Sadeghi R.
        • Agin K.
        • Taherkhani M.
        • Najm-Afshar L.
        • Nelson L.S.
        • Abdollahi M.
        • et al.
        Report of methamphetamine use and cardiomyopathy in three patients.
        Daru. 2012; 20: 1-4
        • Neeki M.M.
        • Kulczycki M.
        • Toy J.
        • Dong F.
        • Lee C.
        • Borger R.
        • et al.
        Frequency of methamphetamine use as a major contributor toward the severity of cardiomyopathy in adults≤ 50 years.
        Am J Cardiol. 2016; 118: 585-589
        • Maddox Thomas M.
        • Januzzi James L.
        • Allen Larry A.
        • Breathett K.
        • Butler J.
        • Davis Leslie L.
        • et al.
        2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.
        J Am Coll Cardiol. 2021; 77: 772-810
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • Bueno H.
        • Cleland J.G.F.
        • Coats A.J.S.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Dalia T.
        • Lahan S.
        • Ranka S.
        • Goyal A.
        • Zoubek S.
        • Gupta K.
        • et al.
        Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis.
        Thromb J. 2021; 19: 7
        • Robinson A.A.
        • Trankle C.R.
        • Eubanks G.
        • Schumann C.
        • Thompson P.
        • Wallace R.L.
        • et al.
        Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi.
        JAMA Cardiol. 2020; 5: 685-692
        • Paratz E.D.
        • Cunningham N.J.
        • MacIsaac A.I.
        The cardiac complications of methamphetamines.
        Heart Lung Circ. 2016; 25: 325-332
        • Bhatia H.S.
        • Nishimura M.
        • Dickson S.
        • Adler E.
        • Greenberg B.
        • Thomas I.C.
        Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation.
        Heart. 2021; 107: 741
        • Køber L.
        • Thune J.J.
        • Nielsen J.C.
        • Haarbo J.
        • Videbæk L.
        • Korup E.
        • et al.
        Defibrillator implantation in patients with nonischemic systolic heart failure.
        N Engl J Med. 2016; 375: 1221-1230
        • Beggs S.A.S.
        • Jhund P.S.
        • Jackson C.E.
        • McMurray J.J.V.
        • Gardner R.S.
        Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.
        Heart. 2018; 104: 144-150
        • Feldman D.
        • Pamboukian S.V.
        • Teuteberg J.J.
        • Birks E.
        • Lietz K.
        • Moore S.A.
        • et al.
        The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary.
        J Heart Lung Transplant. 2013; 32: 157-187
        • Cogswell R.
        • Smith E.
        • Hamel A.
        • Bauman L.
        • Herr A.
        • Duval S.
        • et al.
        Substance abuse at the time of left ventricular assist device implantation is associated with increased mortality.
        J Heart Lung Transplant. 2014; 33: 1048-1055
        • Sharkey K.
        • Gillam L.
        Should patients with self-inflicted illness receive lower priority in access to healthcare resources? Mapping out the debate.
        J Med Ethics. 2010; 36: 661-665
        • Stokes M.
        • Fernando H.
        • Taylor A.
        Cardiogenic shock secondary to methamphetamine induced cardiomyopathy requiring veno-arterial extra-corporeal membrane oxygenation.
        Int J Cardiol. 2016; 207
        • Gowing L.
        • Holmwood C.
        Management of patients presenting with acute methamphetamine-related problems: evidence summary.
        Drug & Alcohol Services South Australia (DASSA), 2017
        • Karila L.
        • Weinstein A.
        • Aubin H.-J.
        • Benyamina A.
        • Reynaud M.
        • Batki S.L.
        Pharmacological approaches to methamphetamine dependence: a focused review.
        Br J Clin Pharmacol. 2010; 69: 578-592
        • Pérez-Mañá C.
        • Castells X.
        • Torrens M.
        • Capellà D.
        • Farre M.
        Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
        Cochrane Database Syst Rev. 2013; Cd009695
        • Minozzi S.
        • Saulle R.
        • De Crescenzo F.
        • Amato L.
        Psychosocial interventions for psychostimulant misuse.
        Cochrane Database Syst Rev. 2016; 9Cd011866
        • Jhanjee S.
        Evidence based psychosocial interventions in substance use.
        Indian J Psychol Med. 2014; 36: 112-118
        • McGovern M.P.
        • Carroll K.M.
        Evidence-based practices for substance use disorders.
        Psychiatr Clin North Am. 2003; 26: 991-1010